SOUTH SAN FRANCISCO, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) — Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Credit Suisse 24th Annual Healthcare Conference on Wednesday, November 11, at 9:30 a.m. Mountain Standard Time at The Phoenician in Scottsdale, Ariz.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism (VTE); andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola’s partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
CONTACT: Investor Contact: Ana Kapor Portola Pharmaceuticals email@example.com Media Contact: Julie Normart W2O Group firstname.lastname@example.org